GlassScriptPhysician profile
Anu Tom Skaria
NPI 1720666852
$4,544.09
in general payments reported to CMS, 2019-2025
22 companies · $596 in 2025
The $596 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $119 · 2022: $1,266 · 2023: $1,763 · 2024: $800 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,091 · Travel and Lodging: $67.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,090.82 |
| Travel and Lodging | $67.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,335.63 | 2022-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Novartis Pharmaceuticals Corporation | $323.20 | 2021-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $265.24 | 2022-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.46 | 2021-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $198.89 | 2023-2024 | Farxiga |
| Cvrx, INC. | $177.53 | 2023 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $157.91 | 2022-2024 | Verquvo |
| Janssen Pharmaceuticals, INC | $142.21 | 2022 | |
| Abiomed | $135.15 | 2023 | Impella |
| E.R. Squibb & Sons, L.L.C. | $121.20 | 2025 | Camzyos |
| Boston Scientific Corporation | $100.00 | 2022 | |
| Bridgebio Pharma, INC. | $93.08 | 2025 | Attruby |
| Impulse Dynamics (USA) INC. | $49.60 | 2023 | Optimizer |
| Amgen INC. | $49.32 | 2021-2023 | Repatha |
| Scpharmaceuticals INC. | $32.46 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Circulation INC | $30.06 | 2021 | |
| Daiichi Sankyo INC. | $26.34 | 2023 | Injectafer |
| Alnylam Pharmaceuticals INC. | $24.93 | 2022 | |
| Medtronic, INC. | $18.00 | 2022 | |
| Biotronik INC. | $14.26 | 2022 | |
| Bausch Health US, LLC | $14.02 | 2021 | |
| Pfizer INC. | $13.60 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anu Skaria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.